On the heels of a PhIII implosion, cancer biotech Mologen is turned over to the liquidator
The 31 staffers left at German biotech Mologen are now working for a liquidator. And the focus now is on finding buyers for anything it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
